A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years .
Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.